| 柳 斌,阳宁静,杨 业.18F-FDG-PET/CT在小细胞肺癌化疗疗效中的评估价值[J].肿瘤学杂志,2018,24(5):439-442. |
| 18F-FDG-PET/CT在小细胞肺癌化疗疗效中的评估价值 |
| The Value of 18F-FDG-PET/CT in Monitoring Chemotherapy Response of Small Cell Lung Cancer |
| 投稿时间：2017-05-09 |
| DOI：10.11735/j.issn.1671-170X.2018.05.B006 |
|
 |
| 中文关键词: 小细胞肺癌 正电子发射计算机断层扫描 药物疗法 |
| 英文关键词:small cell lung cancer positron emission tomography chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 1481 |
| 全文下载次数: 528 |
| 中文摘要: |
| 摘 要：［目的］ 探讨18氟脱氧葡萄糖—正电子发射计算机断层扫描(18fluorodeoxyglucose positron emission computed tomography，18F-FDG-PET) 在检测小细胞肺癌(small cell lung cancer，SCLC)化疗客观疗效中的临床价值。 ［方法］ 68例小细胞肺癌患者入组（广泛期35例、局限期33例），所有患者均行全身化疗，化疗2个周期后根据SUV值及RECIST 标准分别评价疗效，比较两者是否具有一致性，Kaplan-Meier生存分析SUVmax值与患者的生存时间的相关性。［结果］ 18F-FDG-PET代谢缓解与RECIST标准评价的疗效具有明显的一致性(P<0.001)。 ROC曲线分析示SUVmax曲线下面积为0.855，SUVmax值下降>30%患者2年生存率为42.05%，高于SUVmax值下降≤30%者的8.83%(P<0.05)；代谢缓解者（SUVmax值下降>30%）的中位生存时间为21.86个月，明显长于代谢无缓解者（SUVmax值下降≤30%）的9.35个月（χ2=11.928，P=0.001）。［结论］ 18F-FDG-PET能够预测小细胞肺癌化疗的疗效，在小细胞肺癌化疗反应监测中具有一定的临床价值。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the clinical value of 18fluorodeoxyglucose positron emission tomography(18F-FDG-PET) in evaluating chemotherapy response in patients with small cell lung cancer(SCLC). ［Methods］ Sixty eight patients with SCLC，including 33 of limited stage and 35 cases of advanced stage were enrolled in the study. Patients were received systemic chemotherapy and underwent 18F-FDG-PET scan before and after 2 cycles of chemotherapy. The efficacy was evaluated with standard uptake value(SUV) of PET scan and response evaluation criteria in solid tumors (RECIST)，respectively. The survival of patients was measured by Kaplan-Meier curve and the correlation between survival and SUV value was analyzed. ［Results］ The objective curative effect of 18F-FDG-PET metabolic response and RECIST standard evaluation had significant consistency(P<0.001). ROC curve analysis showed the area under the SUV curve was 0.855. The 2-years survival rate in patients with SUVmax decreased >30% was 42.05%，which was higher than that in patients with SUVmax value ≤30% (8.83%，P<0.05). The median survival time in patients with metabolic remission(SUVmax value decreased >30%) was 21.86months，which was significantly longer than that in patients with no metabolic remission(SUVmax decreased≤30%，9.35months) (χ2=11.928，P=0.001). ［Conclusion］ 18F-FDG-PET can predict the efficacy of chemotherapy in small cell lung cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |